Key Insights• The United Kingdom biosurgery market represents a mature and sophisticated national market for surgical biomaterials within Europe, characterized by its universal healthcare system, high standards of clinical care, and significant surgical volumes. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The UK biosurgery market is distinguished by the National Health Service (NHS), which provides publicly funded healthcare to all residents and serves as the primary purchaser and procurer of biosurgical products. According to NHS England data, 8,251,733 episodes with a procedure were performed in NHS providers in 2025/26, alongside 834,803 episodes in independent sector providers. Healthcare expenditure in the UK reached approximately £345 billion in 2025, representing 11.4% of GDP, with government-financed healthcare accounting for 81% of the total. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models, including the expansion of elective surgical hubs and the growing role of independent sector providers.• Bone-Graft Substitutes represent the largest product category within the UK biosurgery market, driven by the high volume of orthopedic procedures. Elective surgical hubs in England performed 385,482 (14.1%) elective procedures in 2024-25, predominantly by orthopedic and ophthalmological specialties.Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive and robotic surgical techniques across NHS hospitals and independent sector providers.• The UK's aging population represents a significant long-term demand driver.

The population aged 65 and over accounted for 20% of the total UK population in 2025, and this proportion continues to rise, increasing the incidence of age-related health issues requiring surgical intervention.The regulatory environment, centered on the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medical Device Regulation (MDR), plays a decisive role in shaping market dynamics. MHRA compliance requirements determine product availability, while NHS procurement policies influence adoption rates across hospital and ambulatory settings.Market Outlook• According to the research report, "United Kingdom Biosurgery Market Overview, 2031 Outlook," published by Actual Market Research, the UK biosurgery market is anticipated to add more than USD 163 Million by 2026-31.• The UK biosurgery market is expected to maintain steady growth through 2031, supported by favorable demographic trends, ongoing technological innovation, and expanding surgical volumes across both NHS and independent sector providers. The market's growth trajectory is intrinsically linked to the broader UK healthcare landscape, including healthcare expenditure, technological adoption, and demographic shifts.• UK healthcare expenditure continues to rise, reaching approximately £345 billion in 2025, representing 11.4% of GDP. Healthcare spending as a share of GDP was 11.4% in 2025, higher than the share of 11.1% in 2024. Government-financed healthcare makes up most healthcare spending in the UK (81% of the total) and was £280 billion in 2025， a real-terms increase of 4.2% from 2024.The aging UK population represents the most significant long-term demand driver. The population aged 65 and over accounted for 20% of the total UK population in 2025, with the over-85s accounting for 3% of the population.

As this demographic expands, the incidence of age-related conditions requiring surgical intervention will increase correspondingly.• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. Elective surgical hubs in England are increasingly adopting robotic procedures, with a higher proportion of colorectal cancer procedures performed robotically in surgical hubs than in other NHS sites. Regulatory support and funding for research and development further foster innovation.Rising surgical procedures are a key driver propelling market expansion. NHS England data shows 8,251,733 episodes with a procedure in NHS providers in 2025/26, with independent sector providers accounting for 834,803 episodes. The increasing volume of surgical procedures creates sustained demand for biosurgical products across all categories.Market DynamicsDriver: High and Growing Surgical Volumes Across All SpecialtiesThe UK performs millions of surgical procedures annually across NHS hospitals, independent sector providers, and elective surgical hubs. According to NHS England data, 8,251,733 episodes with a procedure were performed in NHS providers in 2025/26, alongside 834,803 episodes in independent sector providers.

Elective surgical hubs in England performed 385,482 (14.1%) elective procedures in 2024-25, predominantly by orthopedic and ophthalmological specialties. The breadth and depth of surgical activity in the UK ensure that biosurgical products particularly hemostatic agents and sealants are utilized in virtually every operating room. Healthcare expenditure of approximately £345 billion (11.4% of GDP) provides the financial infrastructure to support expanding surgical volumes. The continued expansion of surgical capacity, driven by the development of elective surgical hubs and the growing role of independent sector providers, further reinforces this demand driver.Challenge: NHS Capacity Constraints and Waiting ListsDespite increasing surgical volumes, the UK healthcare system faces significant capacity constraints that limit the full potential of the biosurgery market. The NHS continues to manage substantial waiting lists, with independent sector provider episodes with a procedure as a percentage of total episodes decreasing from 9.9% in 2023/24 and 2024/25 to 9.2% in 2025/26. Extended wait times reflect systemic capacity limitations including operating room availability, surgical workforce shortages, and hospital bed constraints that restrict the number of procedures that can be performed annually.

For biosurgery manufacturers, this creates a ceiling on immediate revenue growth, as procedure volumes are constrained by healthcare system capacity rather than patient demand alone. Additionally, NHS procurement policies exert significant pricing pressure through centralized negotiations and reference pricing mechanisms.Trend: Expansion of Elective Surgical Hubs and Independent Sector ProvisionThe UK biosurgery market is experiencing a significant structural transformation as surgical care shifts toward elective surgical hubs and independent sector providers. Data from 2019-2025 showed that hubs are providing increasing numbers of procedures, and in 2024-25, 385,482 (14.1%, or around one in seven) elective procedures were performed in a surgical hub. Most surgical hubs facilitate "high-volume low complexity" procedures, predominantly by orthopedic and ophthalmological specialties. During periods of winter pressure, monthly volume of surgery in surgical hubs was maintained while volume of surgery in acute hospitals decreased, as elective care was likely cancelled to accommodate emergency patients. This shift toward dedicated elective facilities creates new opportunities for biosurgical products optimized for high-throughput, low-complexity surgical environments.

The growing role of independent sector providers accounting for 834,803 episodes with a procedure in 2025/26 further diversifies the end-user landscape for biosurgery manufacturers.Policies• The Medicines and Healthcare products Regulatory Agency (MHRA) serves as the competent authority for medical devices in the UK. MHRA regulates biosurgical products under the UK Medical Devices Regulations 2002 (as amended), which align with the European Medical Device Regulation (MDR).• The European Medical Device Regulation (MDR) (EU) 2017/745 continues to influence the UK regulatory landscape. Manufacturers must comply with MDR requirements for clinical evaluation, post-market surveillance, and product labeling to maintain market access.• NHS England procurement policies play a pivotal role in shaping the UK biosurgery market. The NHS Supply Chain operates as the primary procurement channel for biosurgical products, with centralized negotiations influencing pricing and adoption rates across NHS hospitals.• The Health and Care Act 2022 established integrated care systems (ICSs) across England, shifting procurement and commissioning decisions to local level. This decentralization creates both opportunities and challenges for biosurgery manufacturers seeking market access.• Government investment in elective recovery continues to support surgical capacity expansion. The UK Government Evaluation Accelerator Fund (Phase 4, 2025-26) has funded evaluation of elective surgical hubs, reflecting ongoing commitment to surgical capacity development.Segment AnalysisUnited Kingdom Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the UK biosurgery market, driven by the high volume of orthopedic procedures.

Elective surgical hubs in England performed 385,482 (14.1%) elective procedures in 2024-25, predominantly by orthopedic and ophthalmological specialties. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging UK population with 20% aged 65 and older continues to drive demand for musculoskeletal interventions requiring bone-graft substitutes.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. The increasing volume of surgeries and growing demand for effective hemostatic solutions contribute to the strength of this segment.• Surgical Sealants and Adhesives represent the fastest-growing product category in the UK biosurgery market, driven by increasing adoption of minimally invasive and robotic surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses.

Robotic procedures are increasingly performed in surgical hubs and NHS sites, creating demand for sealants compatible with robotic instrumentation.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in NHS hospitals and independent sector providers.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.United Kingdom Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in the UK, driven by the high volume of joint replacement and spinal fusion procedures. Elective surgical hubs predominantly perform orthopedic procedures, reflecting the sustained growth in this specialty. The aging UK population continues to drive demand for musculoskeletal interventions.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair.

Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers. For colorectal cancer surgery, a higher proportion of procedures are performed robotically in surgical hubs than in other NHS sites.• Cardiovascular Surgery represents the fastest-growing application area in the UK biosurgery market, driven by the high prevalence of cardiovascular disease. In the UK there are currently about 7.2 million people diagnosed with cardiovascular disease，which amounts to about 10% of the population. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery. The growing volume of trauma and oncological procedures supports demand in this application.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer.

Cancer remains one of the leading causes of avoidable mortality in England and Wales.United Kingdom Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the UK biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. MHRA's rigorous requirements for biological materials ensure high safety standards and support market confidence.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the UK market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. NHS procurement's emphasis on cost-effectiveness favors synthetic alternatives for certain applications.United Kingdom Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in the UK, accounting for the majority of revenue. NHS hospitals performed 8,251,733 episodes with a procedure in 2025/26, reflecting their central role in surgical care delivery.

The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization.• Ambulatory Surgical Centers (ASCs) and Elective Surgical Hubs represent the fastest-growing end-user segment in the UK biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. In 2024-25, 385,482 (14.1%) elective procedures were performed in surgical hubs. The expansion of dedicated elective facilities supports the adoption of biosurgical products in these settings. Independent sector providers accounted for 834,803 episodes with a procedure in 2025/26.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing. The expansion of outpatient care networks in urban and semi-urban areas supports clinic-based procedure growth.United Kingdom Biosurgery Market Economics• The UK biosurgery market operates within a predominantly publicly funded healthcare system led by the NHS, where centralized procurement and cost containment strongly influence market economics. Healthcare expenditure reached approximately £345 billion in 2025, representing 11.4% of GDP, with government financing accounting for 81% of total spending.

NHS Supply Chain is the primary procurement channel and uses volume-based negotiations to control prices. Manufacturers must demonstrate clinical efficacy, economic value, and cost-effectiveness to secure contracts, while the independent sector, which recorded 834,803 procedure-related episodes in 2025/26, provides an additional commercial channel.• Procurement is increasingly influenced by NHS Supply Chain contracts, Integrated Care System (ICS) agreements, and individual hospital purchasing decisions. This combination of centralized and localized procurement requires manufacturers to balance national pricing strategies with regional requirements. The UK has a well-developed supply chain supported by established distribution networks across England, Scotland, Wales, and Northern Ireland. The country also maintains a strong industrial and commercial base, with companies such as Smith+Nephew demonstrating domestic capabilities. A skilled workforce, advanced infrastructure, and stable healthcare demand continue to support investment in UK biosurgery operations.• The UK has comprehensive healthcare infrastructure spanning NHS hospitals, independent providers, and elective surgical hubs.

In 2024–25, 112 surgical hubs performed 385,482 elective procedures, representing 14.1% of elective procedures, demonstrating their growing role in increasing surgical capacity. The country also benefits from a large and highly trained surgical workforce supported by academic institutions and professional organizations. Strong research capabilities, intellectual property protection, and government-backed initiatives such as the Evaluation Accelerator Fund support innovation in surgical technologies, biomaterials, minimally invasive procedures, and healthcare delivery models.• The regulatory framework is overseen by the Medicines and Healthcare products Regulatory Agency (MHRA) under the UK Medical Devices Regulations 2002, as amended, maintaining rigorous safety and quality requirements. Technology adoption is advancing across robotic-assisted surgery, minimally invasive procedures, and advanced biomaterials, with robotic techniques particularly evident in some surgical hubs. Long-term growth is supported by demographic aging, with approximately 20% of the UK population aged 65 or older and this share continuing to increase. Rising surgical demand, infrastructure investment, technological innovation, and healthcare spending provide a strong foundation for sustained biosurgery market development.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.